Should I buy or sell Oxford Biomedica stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OXBDF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXBDF, but not buy additional shares or sell existing shares. View OXBDF analyst ratings or view top-rated stocks .

How have OXBDF shares performed in 2024?

Oxford Biomedica's stock was trading at $2.69 on January 1st, 2024. Since then, OXBDF stock has decreased by 2.8% and is now trading at $2.6150. View the best growth stocks for 2024 here .

Are investors shorting Oxford Biomedica?

Oxford Biomedica saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,400 shares, an increase of 133.3% from the March 15th total of 600 shares. Based on an average trading volume of 700 shares, the short-interest ratio is currently 2.0 days. View Oxford Biomedica's Short Interest .

How do I buy shares of Oxford Biomedica?

Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:OXBDF

Oxford Biomedica (OXBDF) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free OXBDF Stock Alerts

$2.62

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.62
▼
$2.62
50-Day Range: $2.09
▼
$2.72
52-Week Range: $2.09
▼
$6.02

Volume: N/A
Average Volume: 184 shs
Market Capitalization: $251.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get Oxford Biomedica alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Oxford Biomedica Stock (OTCMKTS:OXBDF)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

OXBDF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OXBDF Stock News Headlines

March 30, 2024 | finance.yahoo.com

Oxford Biomedica Insiders Placed Bullish Bets Worth UK£415.3k

January 23, 2024 | investing.com

Oxford BioMedica PLC (OXB)

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 23, 2024 | finance.yahoo.com

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing

November 5, 2023 | morningstar.com

Oxford BioMedica PLC OXOA

September 25, 2023 | finance.yahoo.com

Analysts Just Slashed Their Oxford Biomedica plc (LON:OXB) EPS Numbers

September 21, 2023 | msn.com

Oxford BioMedica shares boom as manufacturer expands complex cancer therapies

September 20, 2023 | lse.co.uk

Oxford BioMedica shares up, in talks to buy ABL Europe but loss widens

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

September 20, 2023 | msn.com

Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe

September 20, 2023 | marketwatch.com

Oxford BioMedica Shares Rise on Transformational Deal Talks, Revenue Growth Expectation

September 20, 2023 | finance.yahoo.com

Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation

September 20, 2023 | finance.yahoo.com

Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform

September 7, 2023 | finance.yahoo.com

Oxford Biomedica to host webinar showcasing the TetraVecta™ system

July 10, 2023 | finance.yahoo.com

Oxford Biomedica (LON:OXB) shareholders have endured a 50% loss from investing in the stock five years ago

June 23, 2023 | marketwatch.com

Oxford BioMedica's Executive Pay Report Gets Low Shareholder Support at Annual Meeting

February 20, 2023 | finance.yahoo.com

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

January 30, 2023 | finance.yahoo.com

The past year for Oxford Biomedica (LON:OXB) investors has not been profitable

November 14, 2022 | finance.yahoo.com

Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million

September 15, 2022 | lse.co.uk

Oxford BioMedica swings to interim loss as costs climb, revenue falls

August 19, 2022 | finance.yahoo.com

Oxford Biomedica (LON:OXB) shareholders have endured a 66% loss from investing in the stock a year ago

July 26, 2022 | lse.co.uk

Oxford BioMedica begins new project and signs license agreement

July 26, 2022 | finance.yahoo.com

Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy

July 16, 2022 | finance.yahoo.com

Oxford Biomedica plc's (LON:OXB) Intrinsic Value Is Potentially 20% Below Its Share Price

July 1, 2022 | lse.co.uk

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal

July 1, 2022 | seekingalpha.com

AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot

July 1, 2022 | finance.yahoo.com

Oxford BioMedica extends Covid vaccine deal with AstraZeneca

See More Headlines

Receive OXBDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Private households
Sub-Industry: N/A
Current Symbol: OTCMKTS:OXBDF
Previous Symbol: NASDAQ:OXBDF
CUSIP: N/A
CIK: N/A
Web: www.oxfordbiomedica.co.uk
Phone: 44-18-6578-3000
Fax: N/A
Employees: 891
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $173.19 million
Price / Sales: 1.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.03 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 96,260,000
Free Float: N/A
Market Cap: $251.72 million
Optionable: Not Optionable
Beta: 1.15

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Stuart Paynter (Age 52)
CFO & Director
Comp: $1.05M
Dr. Frank Mathias (Age 62)
CEO & Director
Mr. Thierry Cournez
COO & Site Head of UK Operations
Dr. James Miskin Ph.D.
Chief Quality & Technical Officer
Mr. Matthew Treagus
Chief Information Officer & Chief of Staff
Sophia Bolhassan
Head of Investor Relations
Ms. Natalie Louise Walter (Age 51)
General Counsel & Company Secretary
Ms. Lisa James
Chief People Officer
Dr. Kyriacos Mitrophanous Ph.D.
Chief Innovation Officer
Ms. Kati Hudson
Head of Intellectual Property and Contracts

Key Competitors

View All Competitors

OXBDF Stock Analysis - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OXBDF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXBDF, but not buy additional shares or sell existing shares.
View OXBDF analyst ratings or view top-rated stocks.
How have OXBDF shares performed in 2024?: Oxford Biomedica's stock was trading at $2.69 on January 1st, 2024. Since then, OXBDF stock has decreased by 2.8% and is now trading at $2.6150.
View the best growth stocks for 2024 here.
Are investors shorting Oxford Biomedica?: Oxford Biomedica saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,400 shares, an increase of 133.3% from the March 15th total of 600 shares. Based on an average trading volume of 700 shares, the short-interest ratio is currently 2.0 days.
View Oxford Biomedica's Short Interest.
How do I buy shares of Oxford Biomedica?: Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OXBDF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Oxford Biomedica (OXBDF) Stock Price, News & Analysis

About Oxford Biomedica Stock (OTCMKTS:OXBDF)

OXBDF Stock Price History

OXBDF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

OXBDF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info